Medication info
Rosuvastatin Calcium Tablet 10 mg

Rosuvastatin Calcium Tablet 10 mg

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Geonil Biopharm Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201604059 · Approved 2016.06.29 · Insurance code 073001290

Summary

Main use
Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who uses it
Adults
Adult dosage
1. Primary hypercholesterolemia (type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine at 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients.

Ingredients

Manufacturer
Geonil Biopharm Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Hypercholesterolemia
  • hyperlipidemia
  • atherosclerosis
  • dysbetalipoproteinemia
  • cardiovascular disease risk factors
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary artery disease
  • stroke risk
  • myocardial infarction risk
View approved original text

This medicine is primarily used as an adjunct to dietary therapy in cases of lipid disorders such as primary hypercholesterolemia, mixed hyperlipidemia, and familial hypercholesterolemia where diet and exercise are insufficient for control. It also lowers LDL cholesterol and total cholesterol levels, thereby slowing the progression of atherosclerosis. It helps in the treatment of patients with primary dysbetalipoproteinemia and contributes to the reduction of cardiovascular disease risk. In particular, it is used to reduce the risk of stroke, myocardial infarction, and vascular revascularization in high-risk patients with elevated high-sensitivity C-reactive protein levels. Through these effects, it overall improves cardiovascular health.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine at 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients.

Precautions

This medicine should not be used in certain patients. For example, patients who are allergic to this medication's ingredients, those with severely impaired liver function, patients with muscle diseases, patients with severely impaired kidney function, women who are pregnant or breastfeeding, and patients who are taking certain medications should not take this medicine. Before taking this medicine, liver function and muscle status should be thoroughly checked. Patients with poor liver function, hypothyroidism, or muscle problems should use this medicine with caution, and regular liver enzyme and muscle-related tests should be performed even during treatment. This medicine can cause side effects such as myalgia, myopathy, and rarely, severe muscle breakdown (rhabdomyolysis). If symptoms like muscle pain, muscle weakness, or cramping occur, inform a doctor immediately. Furthermore, as this medicine can affect liver function, it should be discontinued immediately if symptoms of jaundice or severe liver damage appear. This medicine may interact with other drugs; therefore, if other medications are being taken, it is essential to inform a doctor or pharmacist. Caution is particularly needed when taken with certain antiviral agents, immunosuppressants, antifungals, antibiotics, and fibrate class medications. Women who are pregnant or at risk of becoming pregnant should not take this medication and should use appropriate contraception if planning to conceive. There is no specific antidote for an overdose, so treatment should be symptomatic according to symptoms, and liver function and muscle enzyme levels should be monitored. Additionally, side effects such as occasional dizziness, headache, dyspepsia, and skin rash may occur during this medication; if symptoms are severe, consult a physician. Finally, this medicine may have higher blood concentrations in Asian individuals; thus, caution is needed when determining the dose.

Side effects

Angioedema, hypersensitivity reaction, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, transaminase increase, Stevens-Johnson syndrome, eosinophilia and systemic symptoms associated drug reaction syndrome, morbilliform drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, ALT increase, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, fatigue, joint pain, acute kidney failure, oliguria, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a tightly sealed container, protected from air and moisture. It is recommended to store it at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.